Quantcast

Latest minimal residual disease Stories

2014-10-09 16:27:54

Additional Global Regulatory Filings Reinforce Commitment to Addressing Significant Unmet Needs for Patients With This Aggressive Cancer With Limited Treatment Options THOUSAND OAKS, Calif., Oct. 9, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for the investigational bispecific T cell engager (BiTE(®)) antibody construct, blinatumomab. The BLA is for the...

2014-09-29 12:29:44

Highly distinguished advisory board to strengthen incorporation of Next Generation Sequencing (NGS) into clinical care for patients with blood cancers SEATTLE, Sept. 29, 2014 /PRNewswire/ -- Adaptive Biotechnologies, a clinical stage diagnostics company that leverages Next Generation Sequencing to profile the adaptive immune system, announced today that it has established a Scientific Advisory Board to provide strategic and clinical guidance for the implementation of its clinical...

2014-09-24 12:29:29

St. Jude Children's Research Hospital study shows that adjusting treatment based on early response to chemotherapy boosts survival of young patients with Philadelphia chromosome-like acute lymphoblastic leukemia MEMPHIS, Tenn., Sept. 24, 2014 /PRNewswire-USNewswire/ -- St. Jude Children's Research Hospital investigators found that adjusting treatment based on early response to chemotherapy made a life-saving difference to young patients with an acute lymphoblastic leukemia (ALL)...

2014-09-22 08:29:14

FDA Submission Reinforces Commitment to Addressing Significant Unmet Needs for Patients With Acute Lymphoblastic Leukemia, an Aggressive Cancer With Limited Treatment Options THOUSAND OAKS, Calif., Sept. 22, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval for its investigational bispecific T cell engager (BiTE(®)) antibody construct, blinatumomab. The BLA is...

2014-08-01 12:26:16

CHICAGO, Aug. 1, 2014 /PRNewswire-USNewswire/ -- The groundbreaking scientific studies featured at the 2014 AACC Annual Meeting & Clinical Lab Expo will include research on a blood test for Alzheimer's that uses biochip technology, a new test to diagnose colon cancer early, a more accurate method for determining multiple myeloma prognosis, a less stressful test for sleep apnea, and the development of a bank of biospecimens from pregnant women that could prove crucial for women's...

2014-07-01 08:29:55

Breakthrough Designation Reinforces Significant Unmet Need in the Treatment of This Highly Aggressive Cancer THOUSAND OAKS, Calif., July 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to investigational bispecific T cell engager (BiTE(®)) antibody blinatumomab, for adults with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL), a rapidly...

2014-06-27 12:26:33

Study published in Clinical Cancer Research and co-led by Adaptive Biotechnologies and the University of Washington demonstrates clinical utility of Next Generation Immune Profiling SEATTLE, June 27, 2014 /PRNewswire/ -- Adaptive Biotechnologies today announced results demonstrating enhanced accuracy and sensitivity of clonoSEQ in identifying risk of relapse in patients with B-cell Acute Lymphoblastic Leukemia (B-ALL), a childhood leukemia, compared to flow cytometry, the current...

2014-06-17 13:07:52

Walter and Eliza Hall Institute of Medical Research Melbourne researchers have shown a type of leukaemia can be successfully ‘reversed’ by coaxing the cancer cells back into normal development. The discovery was made using a model of B-progenitor acute lymphoblastic leukaemia (B-ALL), the most common cancer affecting children. Researchers from the Walter and Eliza Hall Institute showed that switching off a gene called Pax5 could cause cancer in a model of B-ALL, while restoring...

2014-05-05 20:26:04

LONDON, May 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:The World Market for Cancer Diagnostics, 5th Edition: Precision and Personalized Testing Arriveshttp://www.reportbuyer.com/pharma_healthcare/diagnostics/world_market_cancer_diagnostics_5th_edition_precision_personalized_testing_arrives.htmlCancer testing is maturing from personalized medicine to precision medicine, where protein and molecular biomarkers are essential for precise diagnosis,...

2014-01-09 23:01:40

Blinatumomab, the first BiTE® antibody to be developed for the treatment of cancer, is being investigated by the ECOG-ACRIN Cancer Research Group in its latest trial, E1910. Philadelphia, PA (PRWEB) January 09, 2014 The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) announced today that it has activated E1910, a randomized phase III clinical trial comparing overall survival after treatment with blinatumomab in combination with chemotherapy vs. chemotherapy alone in adults aged 35 to...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.